Italian Travel Medicine Society Recommends Chikungunya Vaccination for All Travelers to Endemic Regions

Chikungunya Vaccine Recommendations Expanded Amid Global Spread

Rome, Italy – February 10, 2026 – New Guidance Issued By Italian health Experts Prioritizes Proactive Chikungunya Vaccination For Travelers And Frequent Visitors To Endemic Regions.

The Italian Society of Travel and Migration Medicine (SIMVIM) unveiled updated recommendations on February 6, 2026, regarding the use of the chikungunya vaccine. This comes as the mosquito-borne viral illness continues to expand it’s reach across the globe,impacting areas in Asia,Africa,the Americas,and even occasionally Europe.

Understanding the Chikungunya Threat

Chikungunya Virus, first identified in Africa in the 1950s, causes fever and severe joint pain. While rarely fatal, the illness can be debilitating, and symptoms can persist for weeks, months, or even years according to the Centers for Disease Control and Prevention. Recent outbreaks have spurred concerns and driven the need for enhanced preventative measures.

The collaborative document, created by SIMVIM and SITI (Italian Society of Hygiene, Preventive Medicine and Public Health), directly advises vaccination for individuals planning travel to areas currently experiencing outbreaks. Moreover, the recommendations extend to those residing in or frequently visiting regions where virus transmission has been documented within the past five years.

Who Is Most At Risk?

The guidelines specifically highlight the increased vulnerability of individuals over 65 years of age and those with underlying health conditions.These groups are considered to be at higher risk of developing severe complications from the disease.

Risk Factor	Proposal
Travel to Outbreak Area	Strongly Recommended Vaccination
Residence/Frequent Visits to Endemic Area (Past 5 years)	Recommended Vaccination
Age 65+	Prioritized Vaccination
Underlying Health Conditions	Prioritized Vaccination

A Shift in Prophylaxis Strategies

Andrea Rossanese, President of SIMVIM, emphasized a key distinction in the new recommendations.Unlike approaches taken in othre countries, the Italian guidelines do not correlate the length of stay in a risk area with the necessity for prophylactic measures. “A single mosquito bite can occur at any time, nonetheless of how long someone is visiting,” Rossanese stated.He explained that the cumulative risk from repeated exposure should be a primary consideration for those who travel frequently to endemic zones.

This focus on cumulative exposure signals a proactive stance toward prevention recognizing that even short trips can contribute to a traveller’s overall risk of contracting the virus.

Accessing the Vaccine

Italy boasts an extensive network of over 200 dedicated travellers’ medicine clinics nationwide, providing access to vaccination services. Rossanese urges anyone planning travel to a destination with a risk of Chikungunya – including locations such as Cuba, Brazil, Mexico, and southern China – to consult with a specialized clinic at least 15 days prior to departure.

The updated protocols outlined in the recommendations ensure alignment with existing regulatory standards established internationally.

Looking Ahead

The expansion of vaccination guidelines reflects a growing awareness of the Chikungunya threat and a commitment to protecting public health through preventative strategies.What steps will other nations take in response to these updated recommendations?

Do you think increased access to vaccination will significantly reduce the spread of Chikungunya?

Disclaimer: This article provides general details and should not be considered medical advice. Please consult with a healthcare professional for personalized guidance on vaccination and health precautions.

Share your thoughts in the comments below and help spread awareness about Chikungunya prevention!

What are the reasons behind the Italian Travel Medicine Society’s recommendation for global Chikungunya vaccination among travelers?

Italian Travel Medicine Society Recommends Chikungunya Vaccination for All travelers to Endemic Regions

Published: February 10, 2026 – 13:14:29 on archyde.com

By: Dr. Priya Deshmukh

The Italian Travel Medicine Society (ITMS) has issued a important update to its travel health recommendations, now advising all travelers heading to regions where Chikungunya is endemic to receive vaccination prior to departure. This represents a shift towards proactive prevention, acknowledging the increasing global spread and potential severity of this mosquito-borne viral disease. This article details the implications of this recommendation, the regions at risk, vaccine information, and practical advice for travelers.

Understanding the Chikungunya Threat

Chikungunya fever, while rarely fatal, can cause debilitating joint pain that can persist for weeks, months, or even years. The name itself, derived from a Tanzanian word, means “that which bends up,” describing the contorted posture sufferers often adopt due to joint pain.

* Symptoms: typically appear 3-7 days after a mosquito bite and include fever, joint pain (often severe), muscle pain, headache, rash, and fatigue.

* Severity: While most individuals recover, chronic joint pain is a significant concern, impacting quality of life. Severe cases can involve neurological complications, though these are less common.

* Transmission: Chikungunya is spread through the bite of infected Aedes aegypti and Aedes albopictus mosquitoes. These mosquitoes are also vectors for dengue fever and Zika virus, creating overlapping risk areas.

Regions with Active Chikungunya Transmission

The ITMS recommendation stems from the continued presence of Chikungunya in several global regions. Travelers should be particularly vigilant if visiting:

* Africa: Manny sub-saharan African countries, including Nigeria, Democratic Republic of Congo, and Angola, report ongoing transmission.

* Asia: India, Thailand, Indonesia, Myanmar, and the Philippines are considered high-risk areas. Localized outbreaks are frequently reported.

* The Americas: The Caribbean islands (Dominican Republic, Jamaica, Puerto Rico), Central America, and parts of South America (Brazil, Colombia, Venezuela) continue to experience outbreaks.

* Pacific Islands: Several Pacific Island nations have reported significant Chikungunya activity in recent years.

It’s crucial to check the latest travel health advisories from organizations like the World Health association (WHO) and the Centers for Disease Control and Prevention (CDC) for the most up-to-date information on specific regions. Risk assessments should be made before travel, considering the destination, time of year, and planned activities.

The Chikungunya Vaccine: What You Need to Know

The onyl currently approved Chikungunya vaccine is Ixchiq®, developed by Moderna.

* Approval Status: Approved by the FDA in November 2023, Ixchiq® is available in the United States and is becoming increasingly accessible in other countries, including Italy.

* Dosage: A single dose is administered intramuscularly.

* Efficacy: Clinical trials demonstrated high efficacy in preventing symptomatic Chikungunya infection.

* Who Should Get vaccinated? The ITMS recommends vaccination for all travelers to endemic regions, regardless of age or health status. However, individuals with a history of severe allergic reaction to vaccine components should consult with their physician.

* Timing: Vaccination should ideally be completed at least two weeks before travel to allow for optimal immune response.

Beyond Vaccination: Mosquito Bite Prevention

While vaccination offers significant protection, it’s not a complete shield. Robust mosquito bite prevention strategies remain essential:

1. Insect Repellent: Use repellents containing DEET, picaridin, IR3535, or oil of lemon eucalyptus. Apply according to label instructions.
2. Protective Clothing: wear long sleeves, long pants, and socks, especially during peak mosquito activity (dawn and dusk).
3. Mosquito Nets: Sleep under mosquito nets, particularly in areas with poor screening or outdoor sleeping arrangements.
4. Accommodation Choice: Opt for accommodations with air conditioning and well-maintained screens on windows and doors.
5. Environmental Control: Eliminate standing water around your accommodation,as this provides breeding grounds for mosquitoes.

Real-World Example: A Case Study from the Italian Response to the 2018 Chikungunya Outbreak in Gabon

During the 2